Mark Thornton

Mark Thornton, Ph.D., has a diverse work experience in the pharmaceutical industry. Mark is currently the Director of New Product Planning at Shionogi Inc., a position they have held since 2017. Prior to that, they worked at Symbiotec as a Consultant/Scientific Advisor starting in 2019.

From 2015 to 2017, Thornton worked at Sunovion Pharmaceuticals Inc. as a Business Planning and Intelligence Manager. Mark was responsible for strategic planning and analysis during their tenure.

From 2011 to 2015, they held the position of Senior Manager of Corporate Strategy & Planning at Astellas Pharma. In this role, they managed global strategic projects and developed the Astellas EMEA Mid-Term Business Plan.

Before Astellas Pharma, Thornton worked as a Market Intelligence Manager at Lonza from 2010 to 2011. Mark also gained experience as an International Business Analyst at Hoffmann-La Roche from 2007 to 2010.

Thornton's career began in 2002 at Decision Resources, where they served as a Consultant and later became a Senior Analyst. Mark worked at Decision Resources until 2007.

Overall, Thornton's work experience reflects their expertise in strategic planning, business intelligence, and pharmaceutical consulting.

Mark Thornton Ph.D. holds a PhD in HIV Pharmacology from Imperial College London. Mark also obtained an MSc in Cell & Structural Biology from The University of Manchester. Mark attended Trent College, although no specific degree or field of study was provided for this institution.